Literature DB >> 28904197

Differential Inhibitory Receptor Expression on T Cells Delineates Functional Capacities in Chronic Viral Infection.

Jeffrey E Teigler1,2, Gennadiy Zelinskyy3, Michael A Eller1,2, Diane L Bolton1,2, Mary Marovich1,2,4, Alexander D Gordon1,2, Aljawharah Alrubayyi1,2, Galit Alter5, Merlin L Robb1,2, Jeffrey N Martin6, Steven G Deeks7, Nelson L Michael1, Ulf Dittmer3, Hendrik Streeck8,2,9.   

Abstract

Inhibitory receptors have been extensively described for their importance in regulating immune responses in chronic infections and cancers. Blocking the function of inhibitory receptors such as PD-1, CTLA-4, 2B4, Tim-3, and LAG-3 has shown promise for augmenting CD8 T cell activity and boosting pathogen-specific immunity. However, the prevalence of inhibitory receptors on CD4 T cells and their relative influence on CD4 T cell functionality in chronic HIV infection remains poorly described. We therefore determined and compared inhibitory receptor expression patterns of 2B4, CTLA-4, LAG-3, PD-1, and Tim-3 on virus-specific CD4 and CD8 T cells in relation to their functional T cell profile. In chronic HIV infection, inhibitory receptor distribution differed markedly between cytokine-producing T cell subsets with, gamma interferon (IFN-γ)- and tumor necrosis factor alpha (TNF-α)-producing cells displaying the highest and lowest prevalence of inhibitory receptors, respectively. Blockade of inhibitory receptors differentially affected cytokine production by cells in response to staphylococcal enterotoxin B stimulation. CTLA-4 blockade increased IFN-γ and CD40L production, while PD-1 blockade strongly augmented IFN-γ, interleukin-2 (IL-2), and TNF-α production. In a Friend retrovirus infection model, CTLA-4 blockade in particular was able to improve control of viral replication. Together, these results show that inhibitory receptor distribution on HIV-specific CD4 T cells varies markedly with respect to the functional subset of CD4 T cells being analyzed. Furthermore, the differential effects of receptor blockade suggest novel methods of immune response modulation, which could be important in the context of HIV vaccination or therapeutic strategies.IMPORTANCE Inhibitory receptors are important for limiting damage by the immune system during acute infections. In chronic infections, however, their expression limits immune system responsiveness. Studies have shown that blocking inhibitory receptors augments CD8 T cell functionality in HIV infection, but their influence on CD4 T cells remains unclear. We assessed the expression of inhibitory receptors on HIV-specific CD4 T cells and their relationship with T cell functionality. We uncovered differences in inhibitory receptor expression depending on the CD4 T cell function. We also found differences in functionality of CD4 T cells following blocking of different inhibitory receptors, and we confirmed our results in a Friend virus retroviral model of infection in mice. Our results show that inhibitory receptor expression on CD4 T cells is linked to CD4 T cell functionality and could be sculpted by blockade of specific inhibitory receptors. These data reveal exciting possibilities for the development of novel treatments and immunotherapeutics.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  CD4 T cells; CTLA-4; HIV; PD-1; inhibitory receptors

Mesh:

Substances:

Year:  2017        PMID: 28904197      PMCID: PMC5686724          DOI: 10.1128/JVI.01263-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  81 in total

1.  Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection.

Authors:  Rachael D Aubert; Alice O Kamphorst; Surojit Sarkar; Vaiva Vezys; Sang-Jun Ha; Daniel L Barber; Lilin Ye; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

2.  Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement.

Authors:  P S Linsley; J Bradshaw; J Greene; R Peach; K L Bennett; R S Mittler
Journal:  Immunity       Date:  1996-06       Impact factor: 31.745

3.  Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.

Authors:  Junko Matsuzaki; Sacha Gnjatic; Paulette Mhawech-Fauceglia; Amy Beck; Austin Miller; Takemasa Tsuji; Cheryl Eppolito; Feng Qian; Shashikant Lele; Protul Shrikant; Lloyd J Old; Kunle Odunsi
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-12       Impact factor: 11.205

4.  Simian immunodeficiency virus (SIV) infection of a rhesus macaque induces SIV-specific CD8(+) T cells with a defect in effector function that is reversible on extended interleukin-2 incubation.

Authors:  Y Xiong; M A Luscher; J D Altman; M Hulsey; H L Robinson; M Ostrowski; B H Barber; K S MacDonald
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

5.  The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells.

Authors:  Peter T Sage; Alison M Paterson; Scott B Lovitch; Arlene H Sharpe
Journal:  Immunity       Date:  2014-12-05       Impact factor: 31.745

6.  PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells.

Authors:  Erin E West; Hyun-Tak Jin; Ata-Ur Rasheed; Pablo Penaloza-Macmaster; Sang-Jun Ha; Wendy G Tan; Ben Youngblood; Gordon J Freeman; Kendall A Smith; Rafi Ahmed
Journal:  J Clin Invest       Date:  2013-05-15       Impact factor: 14.808

7.  Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells.

Authors:  Lucy Golden-Mason; Brent E Palmer; Nasim Kassam; Lisa Townshend-Bulson; Stephen Livingston; Brian J McMahon; Nicole Castelblanco; Vijay Kuchroo; David R Gretch; Hugo R Rosen
Journal:  J Virol       Date:  2009-07-08       Impact factor: 5.103

Review 8.  Emerging concepts on T follicular helper cell dynamics in HIV infection.

Authors:  Franco Pissani; Hendrik Streeck
Journal:  Trends Immunol       Date:  2014-04-02       Impact factor: 16.687

9.  Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.

Authors:  Tadashi Yokosuka; Masako Takamatsu; Wakana Kobayashi-Imanishi; Akiko Hashimoto-Tane; Miyuki Azuma; Takashi Saito
Journal:  J Exp Med       Date:  2012-05-28       Impact factor: 14.307

10.  Association of HLA-DRB1-restricted CD4⁺ T cell responses with HIV immune control.

Authors:  Srinika Ranasinghe; Sam Cutler; Isaiah Davis; Richard Lu; Damien Z Soghoian; Ying Qi; John Sidney; Gregory Kranias; Michael D Flanders; Madelene Lindqvist; Bjorn Kuhl; Galit Alter; Steven G Deeks; Bruce D Walker; Xiaojiang Gao; Alessandro Sette; Mary Carrington; Hendrik Streeck
Journal:  Nat Med       Date:  2013-06-23       Impact factor: 53.440

View more
  23 in total

1.  Implications of Immune Checkpoint Expression During Aging in HIV-Infected People on Antiretroviral Therapy.

Authors:  Lesley R de Armas; Suresh Pallikkuth; Stefano Rinaldi; Rajendra Pahwa; Savita Pahwa
Journal:  AIDS Res Hum Retroviruses       Date:  2019 Nov/Dec       Impact factor: 2.205

2.  γδ T cells: an immunotherapeutic approach for HIV cure strategies.

Authors:  Carolina Garrido; Matthew L Clohosey; Chloe P Whitworth; Michael Hudgens; David M Margolis; Natalia Soriano-Sarabia
Journal:  JCI Insight       Date:  2018-06-21

Review 3.  Chimeric antigen receptor T-cell approaches to HIV cure.

Authors:  Anne-Sophie Kuhlmann; Christopher W Peterson; Hans-Peter Kiem
Journal:  Curr Opin HIV AIDS       Date:  2018-09       Impact factor: 4.283

4.  Effect of HIV infection and antiretroviral therapy on immune cellular functions.

Authors:  Marek Korencak; Morgan Byrne; Enrico Richter; Bruce T Schultz; Patrick Juszczak; Julie A Ake; Anuradha Ganesan; Jason F Okulicz; Merlin L Robb; Buena de Los Reyes; Sandra Winning; Joachim Fandrey; Timothy H Burgess; Stefan Esser; Nelson L Michael; Brian K Agan; Hendrik Streeck
Journal:  JCI Insight       Date:  2019-06-20

5.  Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy.

Authors:  Chris Y Chiu; Judy J Chang; Ashanti I Dantanarayana; Ajantha Solomon; Vanessa A Evans; Rachel Pascoe; Céline Gubser; Lydie Trautman; Rémi Fromentin; Nicolas Chomont; James H McMahon; Paul U Cameron; Thomas A Rasmussen; Sharon R Lewin
Journal:  J Immunol       Date:  2021-12-01       Impact factor: 5.422

6.  Loss of Resistance to Mousepox during Chronic Lymphocytic Choriomeningitis Virus Infection Is Associated with Impaired T-Cell Responses and Can Be Rescued by Immunization.

Authors:  Pedro Alves-Peixoto; Maria Férez; Cory J Knudson; Carolina R Melo-Silva; Colby Stotesbury; Eric B Wong; Margarida Correia-Neves; Luis J Sigal
Journal:  J Virol       Date:  2020-02-14       Impact factor: 5.103

7.  Human Immunodeficiency Virus Type-1 Elite Controllers Maintain Low Co-Expression of Inhibitory Receptors on CD4+ T Cells.

Authors:  Kajsa Noyan; Son Nguyen; Michael R Betts; Anders Sönnerborg; Marcus Buggert
Journal:  Front Immunol       Date:  2018-01-22       Impact factor: 7.561

Review 8.  The Role of Immunomodulatory Receptors in the Pathogenesis of HIV Infection: A Therapeutic Opportunity for HIV Cure?

Authors:  Hui Chen; Maha Moussa; Marta Catalfamo
Journal:  Front Immunol       Date:  2020-07-02       Impact factor: 7.561

9.  HIV-1-Specific CAR-T Cells With Cell-Intrinsic PD-1 Checkpoint Blockade Enhance Anti-HIV Efficacy in vivo.

Authors:  Zhengtao Jiang; Huitong Liang; Hanyu Pan; Yue Liang; Hua Wang; Xinyi Yang; Panpan Lu; Xiao Zhang; Jinlong Yang; Dengji Zhang; Xiaoting Shen; Jing Wang; Zhiming Liang; Qinru Lin; Yanan Wang; Lin Zhao; Yangcheng Zhong; Hongzhou Lu; Huanzhang Zhu
Journal:  Front Microbiol       Date:  2021-07-06       Impact factor: 5.640

10.  Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab.

Authors:  Nicolas A Giraldo; Peter Nguyen; Elizabeth L Engle; Genevieve J Kaunitz; Tricia R Cottrell; Sneha Berry; Benjamin Green; Abha Soni; Jonathan D Cuda; Julie E Stein; Joel C Sunshine; Farah Succaria; Haiying Xu; Aleksandra Ogurtsova; Ludmila Danilova; Candice D Church; Natalie J Miller; Steve Fling; Lisa Lundgren; Nirasha Ramchurren; Jennifer H Yearley; Evan J Lipson; Mac Cheever; Robert A Anders; Paul T Nghiem; Suzanne L Topalian; Janis M Taube
Journal:  J Immunother Cancer       Date:  2018-10-01       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.